Xerimis Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Xerimis's estimated annual revenue is currently $24.5M per year.(i)
  • Xerimis's estimated revenue per employee is $201,000

Employee Data

  • Xerimis has 122 Employees.(i)
  • Xerimis grew their employee count by 5% last year.

Xerimis's People

NameTitleEmail/Phone
1
Chief Business OfficerReveal Email/Phone
2
VP, Project ManagementReveal Email/Phone
3
VP Global Business DevelopmentReveal Email/Phone
4
VP Global ProgramsReveal Email/Phone
5
VP Human ResourcesReveal Email/Phone
6
VP Global Business DevelopmentReveal Email/Phone
7
VP OperationsReveal Email/Phone
8
Director Quality AssuranceReveal Email/Phone
9
Director Global Program ManagementReveal Email/Phone
10
APEX Director Clinical Supply Management ServicesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Xerimis?

Founded in 2001, Xerimis is a leading provider of clinical supply services for global trials. Our headquarters in the US and full-service depot in the UK allows for servicing of trials of all sizes anywhere in the world. Serving pharmaceutical, biotechnology, and research organizations, we bring unmatched precision to every stage of your process and trial - from protocol development and plan generation, to labeling, shipping/distribution, and returns reconciliation. Xerimis’s superior standards yield strong client relationships rooted in trust, reliability, and dedication.

keywords:N/A

N/A

Total Funding

122

Number of Employees

$24.5M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$63M2125%N/A
#2
$45.9M232N/AN/A
#3
$66.2M36526%N/A
#4
$185.8M421-5%N/A
#5
$204.3M462-32%N/A